Cargando…

A Risk Model Based on Sorafenib-Response Target Genes Predicts the Prognosis of Patients with HCC

Sorafenib is used to treat digestive system tumors in patients who do not respond to or cannot tolerate surgery. However, the roles and inhibitory mechanisms of sorafenib against hepatocellular carcinoma (HCC) are unclear. Differentially expressed genes in tissues from responders and nonresponders t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Xiang, Zeng, Jian, Li, Huanyu, Li, Feng, Jiang, Bin, Zhao, Ming, Liu, Zhuo, Li, Ruineng, Ma, Tiexiang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9256406/ https://www.ncbi.nlm.nih.gov/pubmed/35799605 http://dx.doi.org/10.1155/2022/7257738

Ejemplares similares

MEX3A knockdown inhibits the tumorigenesis of colorectal cancer via modulating CDK2 expression
por: Zhou, Xin, et al.
Publicado: (2021)

Liver kinase B1 in exosomes inhibits immune checkpoint programmed death ligand 1 and metastatic progression of intrahepatic cholangiocarcinoma
por: Liu, Zhuo, et al.
Publicado: (2022)

Secreted TRAIL gene‐modified adipose‐derived stem cells exhibited potent tumor‐suppressive effect in hepatocellular carcinoma cells
por: Liu, Zhuo, et al.
Publicado: (2020)

Hsa-miR-4277 Decelerates the Metabolism or Clearance of Sorafenib in HCC Cells and Enhances the Sensitivity of HCC Cells to Sorafenib by Targeting cyp3a4
por: He, Xi, et al.
Publicado: (2021)

Predictive and Prognostic Factors in HCC Patients Treated with Sorafenib
por: Brunetti, Oronzo, et al.
Publicado: (2019)

Incapacitated Capicua in Sorafenib-Resistant HCC
por: Yin, Dingzi, et al.
Publicado: (2020)

Dual Targeting of Sorafenib-Resistant HCC-Derived Cancer Stem Cells
por: Shrestha, Ritu, et al.
Publicado: (2021)

Mechanism of sorafenib resistance associated with ferroptosis in HCC
por: Guo, Lingling, et al.
Publicado: (2023)

Cyproheptadine significantly improves the overall and progression-free survival of sorafenib-treated advanced HCC patients
por: Feng, Yu-Min, et al.
Publicado: (2015)

Metformin Resensitizes Sorafenib-Resistant HCC Cells Through AMPK-Dependent Autophagy Activation
por: Lai, Hong-Yue, et al.
Publicado: (2021)

GHR knockdown enhances the sensitivity of HCC cells to sorafenib
por: Gao, Shuang, et al.
Publicado: (2020)

Changing TACTICS in intermediate HCC: TACE plus sorafenib
por: Radu, Pompilia, et al.
Publicado: (2020)

Mutational and transcriptional alterations and clinicopathological factors predict the prognosis of stage I hepatocellular carcinoma: Prediction of stage I HCC prognosis
por: Li, Zhiqiang, et al.
Publicado: (2022)

Sorafenib for advanced hepatocellular carcinoma (HCC): impact of rationing in the United Kingdom
por: Palmer, D H, et al.
Publicado: (2013)

The Enhanced Metastatic Potential of Hepatocellular Carcinoma (HCC) Cells with Sorafenib Resistance
por: Chow, Ariel Ka-Man, et al.
Publicado: (2013)

The Mechanism of Rac1 in Regulating HCC Cell Glycolysis Which Provides Underlying Therapeutic Target for HCC Therapy
por: Ren, Yin-Xiang, et al.
Publicado: (2022)

The Association of HMGB1 Gene with the Prognosis of HCC
por: Xiao, Jianbiao, et al.
Publicado: (2014)

Prognosis Prediction of CRAFITY Score in HCC Undergoing TACE Combined with PD-(L)1 Inhibitors and Molecular Targeted Therapy
por: Hu, Ze-Xin, et al.
Publicado: (2023)

Sorafenib in the Treatment of Virus-Related HCC: Differences Between HCV and HBV
por: De Matteis, Serena, et al.
Publicado: (2021)

Efficacy evaluation of the combination therapy of sorafenib and transarterial chemoembolization for unresectable HCC: a systematic review and meta-analysis of comparative studies
por: Li, Huichen, et al.
Publicado: (2020)

miR-369 inhibits Liver Cancer progression by targeting ZEB1 pathway and predicts the prognosis of HCC patients
por: Dong, Yuwei, et al.
Publicado: (2021)

Combination Therapy of Sorafenib and TACE for Unresectable HCC: A Systematic Review and Meta-Analysis
por: Liu, Lei, et al.
Publicado: (2014)

KIF14 and KIF23 Promote Cell Proliferation and Chemoresistance in HCC Cells, and Predict Worse Prognosis of Patients with HCC
por: Cheng, Chunxia, et al.
Publicado: (2020)

Cuproptosis-related prognostic signatures predict the prognosis and immunotherapy in HCC patients
por: Peng, Hong, et al.
Publicado: (2023)

Eleven metabolism‑related genes composed of Stard5 predict prognosis and contribute to EMT phenotype in HCC
por: Li, Dongping, et al.
Publicado: (2023)

Tumor SOCS3 methylation status predicts the treatment response to TACE and prognosis in HCC patients
por: Jiang, Bei-Ge, et al.
Publicado: (2017)

Sorafenib and Mesenchymal Stem Cell Therapy: A Promising Approach for Treatment of HCC
por: Hajighasemlou, Saieh, et al.
Publicado: (2020)

Elucidating the Molecular Basis of Sorafenib Resistance in HCC: Current Findings and Future Directions
por: Fornari, Francesca, et al.
Publicado: (2021)

LXR activation potentiates sorafenib sensitivity in HCC by activating microRNA-378a transcription
por: Lin, Zhongjie, et al.
Publicado: (2020)

A synthetic dsRNA, as a TLR3 pathwaysynergist, combined with sorafenib suppresses HCC in vitro and in vivo
por: Xu, Yu-Yin, et al.
Publicado: (2013)

Overexpression of PD-L1 is an Independent Predictor for Recurrence in HCC Patients Who Receive Sorafenib Treatment After Surgical Resection
por: Tan, Yifei, et al.
Publicado: (2022)

The role of LDH serum levels in predicting global outcome in HCC patients treated with sorafenib: implications for clinical management
por: Faloppi, Luca, et al.
Publicado: (2014)

Case Report: Severe rash/desquamation induced by sorafenib in an uHCC patient and its clinical management
por: Lin, Yan, et al.
Publicado: (2022)

Novel Prognostic Nomograms for Predicting Early and Late Recurrence of Hepatocellular Carcinoma After Curative Hepatectomy
por: Xu, Wei, et al.
Publicado: (2020)

Comparison of the effect on the prognosis of HCC in terms of different surgical approaches for hepatic inflow occlusion
por: Li, Hong-Hao, et al.
Publicado: (2019)

Development of an Aerobic Glycolysis Index for Predicting the Sorafenib Sensitivity and Prognosis of Hepatocellular Carcinoma
por: Pan, Yu, et al.
Publicado: (2021)

Validation of a Lab-on-Chip Assay for Measuring Sorafenib Effectiveness on HCC Cell Proliferation
por: Piccinno, Emanuele, et al.
Publicado: (2021)

Exosomes derived from HCC cells induce sorafenib resistance in hepatocellular carcinoma both in vivo and in vitro
por: Qu, Zhen, et al.
Publicado: (2016)

Decreased Expression of ZWINT is Associated With Poor Prognosis in Patients With HCC After Surgery
por: Yang, Xiao-Yu, et al.
Publicado: (2018)

Vimentin as a potential therapeutic target in sorafenib resistant HepG2, a HCC model cell line
por: Makol, Ankita, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_rniir303vec0o1uh1sjid739cr